Symbol | Exchange | Currency |
|---|
The moving averages on the daily timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment -- meaning the shorter durations are above the...
Evercore ISI analyst Elizabeth Anderson CFA maintained a Buy rating on Charles River Laboratories Intl on Friday, setting a price target of $395, which is approximately 16.87%...
Credit Suisse (SIX:CSGN) analyst Erin Wright maintained a Hold rating on Charles River Laboratories Intl on Friday, setting a price target of $352, which is approximately 5.96%...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,699.30 | 2,706.10 | 2,685.60 | -16.3 | -0.60% | 695.06K | NASDAQ | |||
| 357.58 | 360.73 | 352.96 | -0.74 | -0.21% | 10.05M | NASDAQ | |||
| 326.53 | 349.15 | 310.00 | +59.74 | +22.39% | 4.35M | NASDAQ | |||
| 72.40 | 72.47 | 70.63 | +3.36 | +4.87% | 3.26M | NYSE | |||
| 121.79 | 122.95 | 121.64 | -0.59 | -0.48% | 2.80M | NASDAQ | |||
| 194.91 | 196.30 | 192.64 | -1.71 | -0.87% | 11.55M | NASDAQ | |||
| 21.67 | 21.99 | 21.59 | -0.14 | -0.64% | 5.44M | NYSE | |||
| 205.72 | 208.52 | 203.24 | -6.84 | -3.22% | 3.73M | NYSE | |||
| 58.32 | 60.88 | 58.01 | -13.72 | -19.05% | 58.73M | NYSE | |||
| 37.41 | 39.19 | 37.31 | -0.72 | -1.89% | 36.46M | NYSE | |||
| 53.68 | 53.89 | 53.25 | -0.02 | -0.04% | 7.97M | NASDAQ | |||
| 194.94 | 196.04 | 190.55 | -2.60 | -1.32% | 12.10M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 57.01 | 57.25 | 56.96 | -0.04 | -0.07% | 3.59M | NYSE | |||
| 190.29 | 190.91 | 188.50 | +0.46 | +0.24% | 1.07M | NASDAQ |
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
